Miluska Castillo
Overview
Explore the profile of Miluska Castillo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
460
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Castaneda C, Castillo M, Sanchez J, Bernabe L, Tello K, Suarez N, et al.
Ecancermedicalscience
. 2024 Oct;
18:1779.
PMID: 39430073
Background: CD44 is a cell-surface transmembrane glycoprotein that participates in the regulation of many cellular processes, including cell division, adhesion, migration and stem-like characteristics. CD63 is involved in the exocytosis...
2.
Castaneda C, Castillo M, Bernabe L, Sanchez J, Fassan M, Tello K, et al.
World J Gastrointest Oncol
. 2024 Jul;
16(6):2487-2503.
PMID: 38994161
Background: The influence of () infection and the characteristics of gastric cancer (GC) on tumor-infiltrating lymphocyte (TIL) levels has not been extensively studied. Analysis of infiltrating-immune-cell subtypes as well as...
3.
Ledesma D, Marques-Piubelli M, Li-Ning-Tapia E, Hudgens C, Gu J, Lazcano R, et al.
Am J Dermatopathol
. 2024 May;
46(7):410-415.
PMID: 38718197
Acral lentiginous melanoma (ALM) is an aggressive type of cutaneous melanoma (CM) that arises on palms, soles, and nail units. ALM is rare in White population, but it is relatively...
4.
Castaneda C, Castillo M, Bernabe L, Suarez N, Romero A, Sanchez J, et al.
Asian Pac J Cancer Prev
. 2022 Oct;
23(10):3331-3337.
PMID: 36308356
Objective: To evaluate the relationship between circulating tumor DNA (ctDNA) presence and tumor features including tumor-infiltrating lymphocyte (TIL) levels in Peruvian breast cancer patients. Materials And Methods: This was a...
5.
Castaneda C, Castillo M, Bernabe L, Suarez N, Fassan M, Sanchez J, et al.
Ecancermedicalscience
. 2022 Jun;
16:1362.
PMID: 35685959
Objective: Epstein-Barr virus (EBV) and (HP) infections have been extensively recognised as gastric cancer (GC) triggers, and recent publications suggest they could behave as predictive markers for immune-modulating therapies. Tumour-infiltrating...
6.
Calderon G, Castaneda C, Castillo M, Sanchez J, Bernabe L, Suarez N, et al.
Asian Pac J Cancer Prev
. 2022 May;
23(5):1571-1576.
PMID: 35633540
Objective: To evaluate the frequency distribution of viral infections in Peruvian Breast Cancer (BC) lesions and its association with clinicopathological features. Additionally, a prospective evaluation of p16 and Tumor-infiltrating lymphocytes...
7.
El Bairi K, Haynes H, Blackley E, Fineberg S, Shear J, Turner S, et al.
NPJ Breast Cancer
. 2021 Dec;
7(1):150.
PMID: 34853355
The advent of immune-checkpoint inhibitors (ICI) in modern oncology has significantly improved survival in several cancer settings. A subgroup of women with breast cancer (BC) has immunogenic infiltration of lymphocytes...
8.
Castaneda C, Castillo M, Bernabe L, Sanchez J, Torres E, Suarez N, et al.
World J Clin Oncol
. 2021 Nov;
12(10):926-934.
PMID: 34733614
Background: Breast cancer (BC) frequency in males is extremely low and tumor features vary from its female counterpart. Breast cancer clinical and pathological features differ by race in women. Tumor...
9.
Sichero L, Tagliabue M, Mota G, Ferreira S, Nunes R, Castaneda C, et al.
Head Neck
. 2021 Nov;
44(1):122-133.
PMID: 34726297
Background: Human papillomavirus (HPV)-driven head/neck squamous cell carcinomas (HNSCC) prevalence varies globally. We evaluated HPV DNA and p16 in formalin fixed paraffin embedded (FFPE) HNSCC from Argentina, Brazil, Colombia, and...
10.
Enciso-Benavides J, Alfaro L, Castaneda-Altamirano C, Rojas N, Gonzalez-Cabeza J, Enciso N, et al.
Heliyon
. 2021 Jul;
7(6):e07273.
PMID: 34235281
Triple-negative breast tumours (TNBTs) make up 15-20% of all breast tumours. There is no treatment for them, and the role that cancer stem cells (CSCs) have in carcinogenesis is still...